• Mashup Score: 32
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer | NEJM - 2 year(s) ago

    Original Article from The New England Journal of Medicine — 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Source: New England Journal of Medicine
    Categories: Hematologists1, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of drkpavithran
      drkpavithran

      No benefit from adjuvant chemotherapy in postmenopausal women with 1-3 positive lymph nodes and a recurrence score of 25 or lower- RxPONDER https://t.co/xoknCTshun

    • Profile photo of tmprowell
      tmprowell

      #RxPONDER trial presented at #SABCS20 now published in @nejm: https://t.co/PAZ8xsLmNb. Congrats to Dr. @KalinskyKevin & all of the authors for this important work! #bcsm #OncTwitter https://t.co/5pn3rrZo2B

    • Profile photo of dradityabardia
      dradityabardia

      RxPONDER finally out ⁦⁦⁦⁦@NEJM. PreM pts with 1-3 LNs & RS <=25, chemoendocrine rx had longer iDFS than endocrine-only; postmenopausal pts did not benefit from chemo. Thanks ⁦@KalinskyKevin⁩ ⁦@SWOG for study⁩. ⁦@OncoAlert⁩ https://t.co/CW02bH0yka

  • Mashup Score: 21
    Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis - 3 year(s) ago

    PURPOSE Many patients and physicians remain concerned about the potential detrimental effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and maternal safety. This systematic review and meta-analysis aimed at providing updated evidence on these topics. METHODS A systematic literature review was conducted to identify studies including patients with a pregnancy after BC…

    Source: Journal of Clinical Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of matteolambe
      matteolambe

      Honored and excited to share our large #metanalysis presented at #SABCS20 now published in @ASCO_pubs #JCO providing solid and reassuring evidence on fetal and maternal safety of #pregnancy after prior #BreastCancer history @OncoAlert #SurvOnc #bcsm Link: https://t.co/lgKQDeB2VS https://t.co/rTpFKsrpMc

  • Mashup Score: 13
    Sacituzumab Shines in ASCENT TNBC Trial - 3 year(s) ago

    The novel antibody–drug conjugate sacituzumab govitecan-hziy has provided an overall survival benefit over conventional chemotherapy for patients with advanced triple-negative breast cancer, according to results of the multicenter phase 3 ASCENT trial. A biomarker analysis of the data shows clinical benefit with was found regardless of level of trophoblast cell-surface antigen-2 expression.

    Source: www.clinicaloncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ClinOncNews
      ClinOncNews

      Sacituzumab provided an overall survival benefit over conventional chemotherapy for patients with advanced TNBC. https://t.co/Dwfy6hoFvG @ABhealer108 @DrWGradishar #sacituzumab #breastcancer #ESMO20 #SABCS20

  • Mashup Score: 7
    Sacituzumab Shines in ASCENT TNBC Trial - 3 year(s) ago

    The novel antibody–drug conjugate sacituzumab govitecan-hziy has provided an overall survival benefit over conventional chemotherapy for patients with advanced triple-negative breast cancer, according to results of the multicenter phase 3 ASCENT trial. A biomarker analysis of the data shows clinical benefit with was found regardless of level of trophoblast cell-surface antigen-2 expression.

    Source: www.clinicaloncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ClinOncNews
      ClinOncNews

      Sacituzumab provided an overall survival benefit over conventional chemotherapy for patients with advanced TNBC. https://t.co/Dwfy6hGgUg @ABhealer108 @DrWGradishar #sacituzumab #breastcancer #ESMO20 #SABCS20

  • Mashup Score: 2
    Ann Partridge on ER+, HER2– Breast Cancer More Effective Treatments Needed - The ASCO Post - 3 year(s) ago

    2020 San Antonio Breast Cancer Symposium Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III estrogen receptor–positive and HER2-negative breast cancer that is resistant to endocrine therapy. The findings…

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed https://t.co/m62kcOF9jm #bcsm #oncology #cancer #SABCS20 @YoungStrongDFCI https://t.co/ZSLBJkYiFp

  • Mashup Score: 1
    Elizabeth Mittendorf on Local Regional Management Following Neoadjuvant Therapy - The ASCO Post - 3 year(s) ago

    2020 San Antonio Breast Cancer Symposium Elizabeth A. Mittendorf, MD, PhD, of Brigham and Women’s Hospital, summarizes her plenary talk, which featured the uncertainties in treatment knowledge: excision of postchemotherapy calcifications; the best sentinel lymph node biopsy technique for patients with node-positive disease who convert to node-negative…

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture at #SABCS20: Local Regional Management Following Neoadjuvant Therapy https://t.co/j0MvR1PTZ1 #bcsm #oncology #cancer @DanaFarber @BrighamWomens https://t.co/Ium6thCiB5

  • Mashup Score: 3
    Updates From Selected Clinical Trials in Breast Cancer - The ASCO Post - 3 year(s) ago

    ‘Best of SABCS’ From Jame Abraham, MD, FACP By Caroline Helwick Posted: 3/1/2021 11:47:00 AM Last Updated: 3/1/2021 1:35:39 PM Jame Abraham, MD, FACP Each year, following the San Antonio Breast Cancer Symposium (SABCS), The ASCO Post asks Jame Abraham, MD, FACP, to offer his…

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Updates From Selected Clinical Trials in Breast Cancer: ‘Best of SABCS’ From Jame Abraham, MD, FACP https://t.co/lZXOleqFiO #bcsm #oncology #cancer #SABCS20 #clinicaltrials @jamecancerdoc https://t.co/N0J1uzRqSb

  • Mashup Score: 2
    SABCS highlights: RxPONDER - 3 year(s) ago

    Roisin Connolly, MD, University College Cork, Cork, Ireland outlines the RxPONDER trial (NCT01272037) which supports the paradigm of moving away…

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: SABCS highlights: RxPONDER w/ @RoisinMConnolly of @UCC and @JohnsHopkins 👉https://t.co/joQJhP4Qcu👈 @VJOncology @OncoAlert @SABCSSanAntonio #SABCS20 #BCsm #BreastCancer #OncoAlert #Oncology #ClinOnc #MedOnc

Load More